Teva Pharmaceutical Industries Ltd (ADR) (TEVA): Fremanezumab Can Take The Pain

Teva Pharmaceutical Industries Ltd (ADR) (TEVA): Fremanezumab Can Take The Pain

Cantor Fitzgerald thinks Teva's fremanezumab has the potential to be the leading CGRP in the market if it is approved


Regeneron Pharmaceuticals Inc (REGN): Expert Sees RTH258 Data As Exciting and Looks To AAO For Full Detail

Jefferies hosted an investor event with a retina expert to discuss the recent Regeneron's RTH258 data and the wet AMD space in general

Amgen, Inc. (NASDAQ:AMGN) Growth Inflection Could Take Time To Play Out

Deutsche Bank believes external headwinds have impacted the company's ability to fully monetize these breakthroughs and hence contribute to the relatively modest current growth profile

Biogen Inc. (BIIB) Getting the Right Stuff . . . Right

Deutsche Bank takes a different tack on Biogen (vs. the prevailing outlook) and focus on earnings power and execution, and hence believe that in the near-term, investors should revisit Biogen under a slightly different lens

Deutsche Bank On Gilead Sciences Inc. (NASDAQ:GILD)

Deutsche Bank expects the disconnect to normalize over the next 12mos, and hence see the current value as an opportunity for investors

Amgen, Inc. (AMGN) Biosimilar Manufacturing Is Not Trivial

MGN’s January 2017 agreement with DVA ensures that at least 90% of DVA’s erythropoiesis-stimulating agents (ESA) be supplied by Amgen, protecting its ESA volume through 2022. DVA controls ~1/3 of ESA market in the US

Here's Why Leerink Analyst Sees About 15% Melt Up Potential in Biotech Names

Achievable financing numbers, strong product launches, positive regulatory activity, and potential guidance increases will drive upside in biotech shares